Mark Kowalski Net Worth

Mark Kowalski biography

Dr. Mark Kowalski, M.D. Ph.D., serves as Chief Medical Officer of the Company. Previously, Dr. Kowalski served as the Chief Medical Officer and Senior Vice President at Arbutus Biopharma (formerly Tekmira Pharmaceuticals), a biotechnology company, from August 2013 to September 2016. Prior to that, Dr. Kowalski worked at Gilead Sciences, Inc. from February to August 2013 following Gilead’s acquisition of YM BioSciences Inc., at which Dr. Kowalski had been Chief Medical Officer and Vice President of Regulatory Affairs from November 2010. Dr. Kowalski previously held the position of Chief Medical Officer of Viventia Biotech, a privately-held biotechnology company, which sought protection from creditors under the Companies’ Creditors Arrangement Act in April 2008 in Ontario, Canada. Dr. Kowalski holds a B.A. from Rutgers University and an M.D. and Ph.D. from the University of Kansas School of Medicine.

What is the salary of Mark Kowalski?

As the Chief Medical Officer of Sierra Oncology Inc, the total compensation of Mark Kowalski at Sierra Oncology Inc is $897,501. There are 1 executives at Sierra Oncology Inc getting paid more, with Barbara Klencke having the highest compensation of $971,397.

How old is Mark Kowalski?

Mark Kowalski is 65, he's been the Chief Medical Officer of Sierra Oncology Inc since 2017. There are 2 older and 15 younger executives at Sierra Oncology Inc. The oldest executive at Sierra Oncology Inc is Robert Pelzer, 66, who is the Independent Chairman of the Board.

What's Mark Kowalski's mailing address?

Mark's mailing address filed with the SEC is C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO, CA, 94404.

Insiders trading at Sierra Oncology Inc

Over the last 8 years, insiders at Sierra Oncology Inc have traded over $0 worth of Sierra Oncology Inc stock and bought 8,528,701 units worth $69,515,388 . The most active insiders traders include Andrew Sinclair, Llp Abingworth, and James N Topper. On average, Sierra Oncology Inc executives and independent directors trade stock every 85 days with the average trade being worth of $21,400,348. The most recent stock trade was executed by William D. Turner on 5 April 2022, trading 6,447 units of SRRA stock currently worth $77,686.

What does Sierra Oncology Inc do?

Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.

Sierra Oncology Inc executives and stock owners

Sierra Oncology Inc executives and other stock owners filed with the SEC include:

• Barbara Klencke,
  Chief Development Officer
• Mark Kowalski,
  Chief Medical Officer
• Sukhi Jagpal,
  Chief Financial Officer
• Dr. Stephen George Dilly M.B.B.S, Ph.D.,
  Pres, CEO & Director
• Dr. Barbara J. Klencke M.D.,
  Chief Medical Officer
• Dr. Mark M. Kowalski M.D., Ph.D.,
  Chief of Research & Early Devel.
• Robert Pelzer,
  Independent Chairman of the Board
• James Smith,
  Vice President Corporate Affairs
• Andrew Sinclair,
  Independent Director
• Josh Richardson,
  Independent Director
• Jeffrey Cooper,
  Independent Director
• Mona Ashiya,
  Independent Director
• Andrew Allen,
  Independent Director
• Gaurav Aggarwal,
  Independent Director
• Craig Collard,
  Director
• William Turner,
  Chief Regulatory and Technical Operations Officer
• Kevin Norrett,
  Chief Business Officer
• Christina Thomson,
  General Counsel
• Stephen Dilly,
  President, Chief Executive Officer, Director
• Kevin Norrett M.B.A., M.S.,
  Chief Bus. Officer
• William D. Turner,
  Chief Regulatory & Technical Operations Officer
• Christina Thomson J.D., M.S.,
  Gen. Counsel, Chief Compliance Officer & Sec.
• Sukhi Jagpal CA, CPA, CBV, MBA,
  Chief Financial Officer
• Daniel Estes,
  Director
• James N Topper,
  Director
• Nicholas Glover,
  CEO and President
• Nicole Onetto,
  Director
• Tran Nguyen,
  Director
• Donald R Parfet,
  Director
• Angie You,
  Chief Bus. & Strat. Officer
• Capital Partners Iii, Llc L...,
  
• Christian Hassig,
  Chief Scientific Officer
• Opportunity, Llc Vivo Oppor...,
  
• Advisors Llcorbimed Capital...,
  
• Opportunity, Llc Vivo Oppor...,
  
• Advisors Llc Orbi Med Capit...,
  
• Georgia Erbez,
  Director
• Christy J. Oliger,
  Director
• Llp Abingworth,
  10% owner
• Mary Christina Thomson,
  General Counsel
• Advisors Llc Orbi Med Capit...,